Contrast agent developers Mallinckrodt of St. Louis and Palatin Technologies of Cranbury, NJ, have extended their marketing agreement for Palatin's NeutroSpec infection imaging agent to include exclusive marketing and distribution rights in Europe.
The original agreement had granted Mallinckrodt an exclusive license to market and distribute NeutroSpec worldwide, excluding Europe. Financial terms were not disclosed.
By AuntMinnie.com staff writers
June 16, 2005
Related Reading
Palatin reports higher sales, lower net loss, May 10, 2005
Palatin nets Medicare reimbursement code, January 24, 2005
Palatin receives milestone payment, August 6, 2004
Mallinckrodt, Palatin get FDA approval, July 6, 2004
Palatin nets $22.7 million, January 30, 2004
Copyright © 2005 AuntMinnie.com
